The influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine

Journal of Clinical Pharmacology

Volumn 38, Issue 5, 1998, Pages 467-474

  Troy, Steven M ^a   Rudolph, Richard ^a   Mayersohn, Michael ^b   Chiang, Soong T ^a  

^a WYETH AYERST RESEARCH   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CIMETIDINE; DRUG METABOLITE; HISTAMINE H2 RECEPTOR ANTAGONIST; VENLAFAXINE;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MENTAL DISEASE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PSYCHOPHARMACOTHERAPY; STEADY STATE;

EID: 0031965952     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04455.x     Document Type: Article

References (18)

1. Moyer JA, Muth EA, Haskins JT, Lappe RW, Sigg EB: In vivo antidepressant profiles of the novel bicyclic compounds Wy-45,030and Wy-45,881 (abstract). Soc Neurosci Abstr 1984;10: 261.
2. Haskins JT, Moyer JA, Muth EA, Sigg EG: Wy-45,030, Wy-45,881 and ciramadol inhibit locus ceruleus neuronal activity. Eur J Pharmacol 1985;115:139-146.
3. Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielsen ST, Sigg EB: Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-4497.
4. Muth EA, Moyer, JA, Haskins JT, Andree TH, Husbands GEM: Biochemical, neurophysiological and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991;23:191-199.
5. Sisenwine SF, Politowski J, Birk K, White G, Dyroff M: A prefatory investigation of the metabolic disposition of Wy-45,030 in man (abstract). Acta Pharmacol Toxicol 1986;59(Suppl 5):312.
6. Fahre LF, Putman HP: An ascending single-dose tolerance study of Wy-45,030, a bicyclic antidepressant, in healthy men. Curr Ther Res Clin Exp 1987;42:901-909.
7. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST: Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992;32:716-724.
8. 2-receptor antagonist drug interactions. J Clin Gastroenterol 1983;5(Suppl): 95-113.
9. Gerber MC, Tejwani GA, Gerber N, Bianchine JR: Drug interactions with cimetidine: an update. Pharmacol Ther 1985;27:353-370.
10. Shinn AF: Clinical relevance of cimetidine drug interactions. Drug Safety 1992;7:245-267.
11. Hicks DR, Wolaniuk D, Russell A, Cavanaugh N, Kraml M: A high-performance liquid chromatographic method for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in biological fluids. Ther Drug Monit 1994;16:100-107.
12. Nitsche V, Mascher H: New rapid assay of cimetidine in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr 1983;273:449-452.
13. SAS Institute: SAS User's Guide: Statistics. Cary, NC: SAS Institute, 1985.
14. Hsu K, Carton A, Sproule BJ, Tam YK, Legatt D, Herbert FA: The influence of orally administered cimetidine and theophylline on the elimination of each drug in patients with chronic airway obstruction. Am Rev Respir Dis 1984;130:740-743.
15. Cremer KF, Secor J, Speeg KV Jr: The effect of route of administration on the cimetidine-theophylline drug interaction. J Clin Pharmacol 1989;29:451-456.
16. Slaughter RL: Theophylline commentary. In, Evans WE, Schentag JJ, Jusko WJ (eds.): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Second edition. Spokane: Applied Therapeutics, 1986;1197-1200.
17. Schoerlin MP, Mayersohn M, Hoevels B, Eggers H, Dellenbach M, Pfeffen JP: Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacol Ther 1991;49:32-38.
18. Feely J, Wilkinson GR, Wood AJJ: Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 1981;304:692-695.